OBJECTIVES: According to the Texas Psychotropic Medication Utilization Parameters for Children, more than two stimulants (e.g., methylphenidate) prescribed concomitantly should be further reviewed unless these two stimulants are the combination of a short acting and a long acting stimulant. The purpose of this study was to identify and assess those concomitant stimulant prescriptions that were subjected to utilization review prescribed in Texas during 2013-2014. METHODS: The Texas prescription drug monitoring program (PDMP) data was used as the data source in this study. The data tracked information related to all schedule-II medications prescribed in Texas. Concomitant prescriptions of stimulants were defined in our study as the existence of any overlap between at least two stimulant prescriptions. The duration of concomitant use and the number of providers involved in concomitant stimulant prescribing were also assessed. Logistic regression was conducted to examine the association between age of patients and likelihood of receiving concomitant stimulant prescriptions. RESULTS: Of the 1,143,161 patients who were dispensed stimulants, 16.6% received concomitant stimulants prescriptions during 2013-2014. Among concomitant stimulant recipients, 63.4% cases (n=120,678) received the combination of two short acting or two long acting stimulants thus were subjected to utilization review. Among this faction, 20.7% cases (n=24,984) received these combinations for more than 30 days (10.05% received for 30-60 days, 4.05% received for 60-90 days and 6.6% received for more than 90 days). The doctors who prescribed the concomitant prescriptions subjected to utilization review for more than 30 days were 35.8% of the total stimulant prescribers (n=5,587). Patients' age was negatively associated with the likelihood of receiving concomitant stimulant prescriptions. CONCLUSIONS:  Concomitant stimulant pharmacotherapy is frequently used in Texas and majority of these concomitant uses were not well justified. Moreover, substantial numbers of providers prescribe concomitant pharmacotherapy that is subjected to drug utilization review.